tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Angioedema D000799 6 associated lipids
Anus Diseases D001004 3 associated lipids
Apraxias D001072 1 associated lipids
Arm Injuries D001134 1 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Ascites D001201 25 associated lipids
Ataxia D001259 20 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Bacterial Infections D001424 21 associated lipids
Balanitis D001446 4 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Behcet Syndrome D001528 7 associated lipids
Biliary Fistula D001658 13 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Blepharitis D001762 4 associated lipids
Blindness D001766 6 associated lipids
Body Weight D001835 333 associated lipids
Bone Diseases D001847 4 associated lipids
Bradycardia D001919 13 associated lipids
Brain Diseases D001927 27 associated lipids
Brain Edema D001929 20 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Burns D002056 34 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Catalepsy D002375 30 associated lipids
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Corneal Diseases D003316 13 associated lipids
Cough D003371 19 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptococcosis D003453 3 associated lipids
Cutis Laxa D003483 1 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Deglutition Disorders D003680 2 associated lipids
Dehydration D003681 11 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Delaney CP et al. Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity. 1996 J. Clin. Invest. pmid:8550837
Tomikawa S et al. Immunosuppressive effects of bactobolamine in vitro and in vivo. 1996 Transplant. Proc. pmid:8623223
Nakajima H and Oka T The inhibition of T-cell-receptor-induced Fas ligand upregulation by cyclosporine and FK 506. 1996 Transplant. Proc. pmid:8623224
Ko S et al. Different immunosuppressive effects of liposomal FK506 in liver and kidney transplantation. 1996 Transplant. Proc. pmid:8623229
Morozumi K et al. A comparative study of morphological characteristics of renal injuries of tacrolimus (FK506) and cyclosporin (CyA) in renal allografts: are the morphologic characteristics of FK506 and CyA nephrotoxicity similar? 1996 Transplant. Proc. pmid:8623232
Takada S et al. HGF prevents tacrolimus (FK 506)-induced nephrotoxicity in SHR rats. 1996 Transplant. Proc. pmid:8623236
Nakai T et al. Immunosuppressive mechanism and immune tolerance of FK 506 in rat small bowel transplantation. 1996 Transplant. Proc. pmid:8623237
Jin MB et al. Protective effect of FK 506 on hepatic energy metabolism in warm ischemic canine livers induced by total hepatic vascular exclusion. 1996 Transplant. Proc. pmid:8623243
Smit JA et al. Induction of primate TH2 lymphokines to suppress TH1 cells. 1996 Transplant. Proc. pmid:8623334
Elmer DS et al. Use of FK506 immunosuppressive therapy in pancreas transplantation. 1996 J Transpl Coord pmid:9188369
Troppmann C et al. Perioperative immunosuppression as a critical determinant of early outcome after discordant xenoislet transplantation: a comparative study. 1996 Transplant. Proc. pmid:8623487
McKenna BA et al. Tacrolimus (FK 506): a whole blood assay as measured on the Abbott IMx analyzer. 1996 Transplant. Proc. pmid:8623491
Stratta RJ et al. FK 506 induction and rescue therapy in pancreas transplant recipients. 1996 Transplant. Proc. pmid:8623492
Birk PE et al. Preliminary experience with FK 506 in pediatric renal transplant recipients: a single-center report. 1996 Transplant. Proc. pmid:8623493
Alloway RR et al. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience. 1996 Transplant. Proc. pmid:8623494
Woodle ES et al. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. 1996 Transplant. Proc. pmid:8623495
Appignani BA et al. Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. 1996 AJR Am J Roentgenol pmid:8623651
Chudek J et al. [The role of endothelin in the physiology and pathophysiology of the circulatory system and kidneys]. 1996 Pol. Arch. Med. Wewn. pmid:9139279
Murao K et al. Immunosuppressant agent FK506 stimulates growth hormone (GH) secretion and gene expression of hypothalamic GH-releasing hormone in the rat. 1996 Endocrinology pmid:8603582
Fay JW et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. 1996 Blood pmid:8605372
Greeno EW et al. Exchange transfusion the hard way: massive hemolysis following transplantation of bone marrow with minor ABO incompatibility. 1996 Transfusion pmid:8607158
Suzuki S et al. Pure red cell aplasia induced by FK506. 1996 Transplantation pmid:8607191
Busuttil RW et al. General guidelines for the use of tacrolimus in adult liver transplant patients. 1996 Transplantation pmid:8607197
Esquivel CO et al. Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. 1996 Transplantation pmid:8607198
Peters KP et al. The automatic search for ligand binding sites in proteins of known three-dimensional structure using only geometric criteria. 1996 J. Mol. Biol. pmid:8609611
Corrigan CJ et al. Glucocorticoid resistant asthma: T-lymphocyte steroid metabolism and sensitivity to glucocorticoids and immunosuppressive agents. 1996 Eur. Respir. J. pmid:8902470
Sakane T and Miura K [Research for basic and clinical aspects of Behcet's disease--recent advance and future--]. 1996 Nippon Rinsho pmid:8904250
Weinzweig N et al. Peripheral-nerve allotransplantation in rats immunosuppressed with transient or long-term FK-506. 1996 J Reconstr Microsurg pmid:8905545
Nagai H et al. The role of interleukin-5 (IL-5) in allergic airway hyperresponsiveness in mice. 1996 Ann. N. Y. Acad. Sci. pmid:8906215
Tsunoda SM and Aweeka FT The use of therapeutic drug monitoring to optimise immunosuppressive therapy. 1996 Clin Pharmacokinet pmid:8906895
Yocum DE Cyclosporine, FK-506, rapamycin, and other immunomodulators. 1996 Rheum. Dis. Clin. North Am. pmid:8907069
Lu YF et al. FK506, a Ca2+/calmodulin-dependent phosphatase inhibitor, inhibits the induction of long-term potentiation in the rat hippocampus. 1996 Neurosci. Lett. pmid:8907327
Sperr WR et al. Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. 1996 J. Allergy Clin. Immunol. pmid:8757216
Ye Q et al. Persistence of donor cells and incidence of graft-versus-host disease after simultaneous small bowel and bone marrow transplantation. 1996 Transplant. Proc. pmid:8907895
Venkataraman L et al. Differential regulation of c-Rel translocation in activated B and T cells. 1996 J. Immunol. pmid:8757620
Brunner T et al. Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. 1996 Int. Immunol. pmid:8757947
Gusev AI et al. A quantitative study of in vitro hepatic metabolism of tacrolimus (FK506) using secondary ion and matrix-assisted laser desorption/ionization mass spectrometry. 1996 Rapid Commun. Mass Spectrom. pmid:8759330
Rokaw MD et al. FK-506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells. 1996 Am. J. Physiol. pmid:8760046
Tomono M et al. Calcineurin is essential for DNA synthesis in Swiss 3T3 fibroblasts. 1996 Biochem. J. pmid:8760349
Becker G et al. Diltiazem minimizes tubular damage due to FK506-mediated nephrotoxicity following ischemia and reperfusion in rats. 1996 Transpl. Immunol. pmid:8762016
Paus R et al. Hair growth control by immunosuppression. 1996 Arch. Dermatol. Res. pmid:8818191
Hisanaga Y et al. Implication of nitric oxide synthase activity in the genesis of water immersion stress-induced gastric lesions in rats: the protective effects of FK506. 1996 Aliment. Pharmacol. Ther. pmid:8971291
Corey HE et al. Improved renal allograft survival in children treated with FK 506 (tacrolimus) rescue therapy. 1996 Pediatr. Nephrol. pmid:8971888
Williams R et al. Two-year data from the European multicentre tacrolimus (FK506) liver study. 1996 Transpl. Int. pmid:8959812
Jonas S et al. Indications for tacrolimus anti-rejection therapy in liver allograft recipients. 1996 Transpl. Int. pmid:8959817
James DG A new immunosuppressant: tacrolimus. 1996 Postgrad Med J pmid:8977938
Gruessner RW et al. Use of FK 506 in pancreas transplantation. 1996 Transpl. Int. pmid:8959841
Weppler D et al. Status of liver and gastrointestinal transplantation at the University of Miami. 1996 Clin Transpl pmid:9286568
Fändrich F et al. Circumvention of natural killer cell and T-cell mediated allogeneic target killing with tacrolimus (FK506) in small bowel transplantation related graft-vs-host disease. 1996 Transpl. Int. pmid:8959843
Antoniou E et al. Effect of RS61443 in combination with leflunomide or FK506 on rat heart allograft survival. 1996 Transpl. Int. pmid:8959858
Golbaekdal K et al. The acute effects of FK-506 on renal haemodynamics, water and sodium excretion and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide and vasopressin in pigs. 1996 J. Pharm. Pharmacol. pmid:8961168
Schumacher G et al. Neurologic symptoms improve in patients with Wilson's disease despite immunosuppression. 1996 Transplant. Proc. pmid:8962200
Sunyecz JA et al. Lymphoproliferative disorder involving the cervix in a patient being treated with FK-506. 1996 Gynecol. Oncol. pmid:8751565
Woodle ES et al. Tacrolimus therapy for refractory acute renal allograft rejection: a prospective multicenter trial. Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplant. Proc. pmid:8962225
Ho SN et al. Dimeric ligands define a role for transcriptional activation domains in reinitiation. 1996 Nature pmid:8752278
Motamedi H et al. Characterization of methyltransferase and hydroxylase genes involved in the biosynthesis of the immunosuppressants FK506 and FK520. 1996 J. Bacteriol. pmid:8752344
Yamashita M et al. Non-T cell-derived IL-4 plays an important role in IgE production induced by antigen resensitization and is resistant to FK506. 1996 J. Immunol. pmid:8752921
Silva ND and Prendergast FG Tryptophan dynamics of the FK506 binding protein: time-resolved fluorescence and simulations. 1996 Biophys. J. pmid:8785272
Wagenknecht T et al. Cryoelectron microscopy resolves FK506-binding protein sites on the skeletal muscle ryanodine receptor. 1996 Biophys. J. pmid:8785329
Dumont FJ et al. Mixed agonist/antagonist activity of an FK-506-related immunosuppressant: biological and biochemical characterization. 1996 J. Pharmacol. Exp. Ther. pmid:8786538
Michel G et al. Antioncogene P53 and mitogenic cytokine interleukin-8 aberrantly expressed in psoriatic skin are inversely regulated by the antipsoriatic drug tacrolimus (FK506). 1996 Biochem. Pharmacol. pmid:8787547
Kershner RP and Fitzsimmons WE Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. 1996 Transplantation pmid:8878385
Nolan TJ and Schad GA Tacrolimus allows autoinfective development of the parasitic nematode Strongyloides stercoralis. 1996 Transplantation pmid:8878405
Devine SM et al. Tacrolimus (FK506)-induced cerebral blindness following bone marrow transplantation. 1996 Bone Marrow Transplant. pmid:8879619
Taylor P et al. Conformational polymorphism in peptidic and nonpeptidic drug molecules. 1996 Biopolymers pmid:9101762
Ikegami S et al. A facilitatory effect on the induction of long-term potentiation in vivo by chronic administration of antisense oligodeoxynucleotides against catalytic subunits of calcineurin. 1996 Brain Res. Mol. Brain Res. pmid:8883951
Soldin SJ Receptor assays in the clinical laboratory. 1996 Clin. Biochem. pmid:8884064
Woodle ES et al. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation. 1996 Clin Transplant pmid:8884103
Karashima T et al. FK506 and cyclosporin A inhibit growth factor-stimulated human keratinocyte proliferation by blocking cells in the G0/G1 phases of the cell cycle. 1996 J. Dermatol. Sci. pmid:8884530
Sakimoto H et al. Administration of tacrolimus (FK506) in hamster-to-rat pancreas xenotransplantation. 1996 Transplant. Proc. pmid:8658727
Monfar M and Blenis J Inhibition of p70/p85 S6 kinase activities in T cells by dexamethasone. 1996 Mol. Endocrinol. pmid:8885245
Takeda M et al. Pretreatment with splenectomy and FK506 in xeno-lung transplantation. 1996 Transplant. Proc. pmid:8658728
Zou XM et al. Immunosuppressive effect of FK506 on orthotopic liver and small bowel xenotransplantation (xenoOLTx and SBTx). 1996 Transplant. Proc. pmid:8658729
Kokado Y et al. Hypertension in renal transplant recipients and its effect on long-term renal allograft survival. 1996 Transplant. Proc. pmid:8658802
Park KM et al. Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. 1996 Transplant. Proc. pmid:8658863
Kakefuda T et al. Detection of nitrosylhemoglobin in liver allograft in rats by using near-infrared spectroscopy. 1996 Transplant. Proc. pmid:8658885
Kawabe A et al. Anti-adhesion (anti-ICAM-1 and anti-LFA-1) therapy in a rat pancreas transplantation model. 1996 Transplant. Proc. pmid:8658893
Hayakawa K et al. Maintenance of unresponsiveness by short-term pulse therapy with FK 506 in rat transplantation. 1996 Transplant. Proc. pmid:8658904
Holt DW et al. Quality assessment issues of new immunosuppressive drugs and experimental experience. 1996 Ther Drug Monit pmid:8857551
McMichael J et al. Computer-guided randomized concentration-controlled trials of tacrolimus in autoimmunity: multiple sclerosis and primary biliary cirrhosis. 1996 Ther Drug Monit pmid:8857564
Bartlett ST et al. Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. 1996 Ann. Surg. pmid:8857849
Takuma T et al. Dephosphorylation of cofilin in parotid acinar cells. 1996 J. Biochem. pmid:8864841
Yamada A et al. Long-term acceptance of major histocompatibility complex-mismatched cardiac allograft induced by a low dose of CTLA4IgM plus FK506. 1996 Microbiol. Immunol. pmid:8865157
Christians U et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. 1996 Br J Clin Pharmacol pmid:8866917
[Tacrolimus--a new perspective in kidney transplantation]. 1996 Urologe A pmid:9022401
Cox KL and Freese DK Tacrolimus (FK506): the pros and cons of its use as an immunosuppressant in pediatric liver transplantation. 1996 Clin Invest Med pmid:8889279
Bashuda H et al. Induction of persistent allograft tolerance in the rat by combined treatment with anti-leukocyte function-associated antigen-1 and anti-intercellular adhesion molecule-1 monoclonal antibodies, donor-specific transfusion, and FK506. 1996 Transplantation pmid:8693525
Fung JJ et al. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. 1996 J. Am. Coll. Surg. pmid:8696542
Shaw LM et al. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. 1996 Clin. Chem. pmid:8697605
Bousvaros A et al. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). 1996 Gastroenterology pmid:8698205
Mach-Pascual S et al. Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. 1996 Am. J. Hematol. pmid:8701950
Hemenway CS and Heitman J Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast. 1996 J. Biol. Chem. pmid:8702500
Chambraud B et al. FAP48, a new protein that forms specific complexes with both immunophilins FKBP59 and FKBP12. Prevention by the immunosuppressant drugs FK506 and rapamycin. 1996 J. Biol. Chem. pmid:8955134
Sano Y et al. Effect of a single injection of high-dose FK506 on lung transplantation in rats. 1996 Surg. Today pmid:9017963
Villalba L and Adams EM Update on therapy for refractory dermatomyositis and polymyositis. 1996 Curr Opin Rheumatol pmid:9018458
Schuetz EG et al. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. 1996 Mol. Pharmacol. pmid:8632764
Sun S et al. Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. 1996 Transplantation pmid:8633368
Kashu Y et al. The effect of combination splenectomy and low-dose FK506 therapy on graft survival after liver allograft transplantation in rats. 1996 Transplantation pmid:8633382
Yoshimura N et al. A case report of pregnancy in renal transplant recipient treated with FK506 (tacrolimus). 1996 Transplantation pmid:8633388
Ohtomo Y et al. C-peptide stimulates rat renal tubular Na+, K(+)-ATPase activity in synergism with neuropeptide Y. 1996 Diabetologia pmid:8635672